IMR Press / FBE / Volume 5 / Issue 2 / DOI: 10.2741/E637

Frontiers in Bioscience-Elite (FBE) is published by IMR Press from Volume 13 Issue 2 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Article

The biological evaluation of ADMA/SDMA and eNOS in patients with ACHF

Show Less
1 Department of Medicine and Science of aging, University G. D’Annunzio, Chieti, Italy
2 Department of Biomedical Science, Clinical Biochemistry, G. D’Annunzio University Chieti, Italy
3 Cardiology Department SS Annunziata Hospital, Via dei Vestini- Chieti Italy, 4San Camillo de Lellis’ Hospital, Cardiology Unit, Italy

*Author to whom correspondence should be addressed.

Academic Editor: Giovanni Li Volti

Front. Biosci. (Elite Ed) 2013, 5(2), 551–557; https://doi.org/10.2741/E637
Published: 1 January 2013
(This article belongs to the Special Issue Biochemical markers in biological fluids)
Abstract

The aim of this study was to investigate the effects of acute pharmacological treatment on the plasma levels of L-arginine, asymmetrical dimethylarginine (ADMA), and symmetrical dimethylarginine (SDMA). We also investigated the related effects on endothelial nitric oxide synthase (eNOS) expression and activity and cytochrome c oxidase activity in the primary blood mononuclear cells (PBMCs) isolated from patients with acute congestive heart failure (ACHF). Compared to pretreatment values, ADMA, SDMA, and L-arginine plasma levels were significantly higher after pharmacological treatment (ADMA, 0.82 versus 0.43 µM; SDMA, 1.52 versus 1.12 µM; L-arginine, 1.78 versus 1.29 µM; p < 0.01. In addition, the levels of eNOS expression and activity were decreased after pharmacological treatment, while cytochrome c oxidase activity resulted in higher O2- production. In the PBMCs isolated from patients with acute congestive heart failure (ACHF) and impaired renal function, higher SDMA and ADMA levels were more evident after therapy, as were reduced expression and activity of eNOS. Increased O2- produced after treatment may be involved in impaired recovery of cardiac function associated with higher plasma levels of SDMA.

Keywords
ADMA
SDMA
NO
eNOS
Acute Heart Failure
Share
Back to top